ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Study sponsor: Jazz Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-12-31Actual
Enrollment · participants73Actual
Source updated2025-07-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.